Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jul 24, 2024; 15(7): 835-839
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.835
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.835
Histologic subtypes of non-muscle invasive bladder cancer
Nicola Giudici, Roland Seiler, Department of Urology, Spitalzentrum Biel, Biel 2501, Switzerland
Roland Seiler, Department of BioMedical Research, University of Bern, Bern 3010, Switzerland
Author contributions: Giudici N performed the majority of the writing and prepared the tables; Seiler R provided input and supervision in writing the paper; Both authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nicola Giudici, MD, Doctor, Department of Urology, Spitalzentrum Biel, Vogelsang 84, Biel 2501, Switzerland. nicolagiudici@gmail.com
Received: March 28, 2024
Revised: May 21, 2024
Accepted: May 30, 2024
Published online: July 24, 2024
Processing time: 109 Days and 19.6 Hours
Revised: May 21, 2024
Accepted: May 30, 2024
Published online: July 24, 2024
Processing time: 109 Days and 19.6 Hours
Core Tip
Core Tip: The currently used classification for histologic subtypes (HS) in urothelial carcinoma has mainly been described in muscle invasive bladder cancer. However, a subset of non-muscle invasive bladder cancer presents HS, and their presence is clinically relevant. In this minireview, we discuss the epidemiology, classification, characterization and the clinical relevance of HS in non-muscle invasive bladder cancer.